MedTrace Logo

A Trial of CM-AT in Children With Autism

NCT00881452 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2018-04-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.

Conditions

Interventions

DRUG

CM-AT

Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days

DRUG

Placebo

Single unit dose powder of non-active substance administered 3 times per day for 90 days

Sponsors & Collaborators

  • Curemark

    lead INDUSTRY

Principal Investigators

  • Eugene Arnold, MD MEd. · Nisonger Center Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-06-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00881452 on ClinicalTrials.gov